Access to Genetic Counselor Services Act of 2026
Summary
The Access to Genetic Counselor Services Act of 2026 expands Medicare coverage for genetic counseling services, creating a new revenue stream for genetic counselors and diagnostic testing companies. This directly increases demand for genetic testing and counseling, benefiting companies involved in these services.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Medicare Part B will cover genetic counseling services starting January 1, 2027.
- 2.This creates a new, significant revenue stream for genetic counselors and related diagnostic testing companies.
- 3.Bipartisan sponsorship increases the bill's likelihood of passage.
Market Implications
The expansion of Medicare coverage for genetic counseling services will drive increased demand for genetic testing, directly benefiting diagnostic companies like LabCorp ($LH) and Quest Diagnostics ($DGX). Healthcare staffing firms, such as AMN Healthcare Services ($AMN), will experience higher demand for genetic counselors. This represents a bullish catalyst for the healthcare sector, specifically for companies involved in genetic diagnostics and counseling services.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Emergency Medical Services Reimbursement for On-Scene and Support Act
Increasing Access to Quality Cardiac Rehabilitation Care Act of 2025
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
Defend Rural Health Act of 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.